CD30 CAR T-cells after stem cell transplant for high-risk Hodgkin lymphoma
Part of Cancer clinical trials.
This trial tests a new treatment using your own immune cells (T-cells) that are specially designed to attack a protein called CD30 found on Hodgkin lymphoma cells. It's given after a stem cell transplant to try to prevent the cancer from coming back in people with high-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 29 years old.
- You have been diagnosed with a type of Hodgkin lymphoma that tests positive for CD30.
- Your disease did not get better with initial treatment, or it came back after treatment (1st, 2nd, or 3rd time).
- You are eligible for a stem cell transplant (using your own cells).
- You have a biopsy (tissue sample) that confirms your lymphoma is still CD30-positive and active.
- You have at least 2 high-risk features, such as low performance status, early relapse, or disease resistant to chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells—specially engineered immune cells designed to target and destroy Hodgkin lymphoma that has come back after initial treatment. It's designed for patients with low-risk disease who respond well to re-induction (initial salvage) therapy.
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a new treatment called CD30 CAR-T, which uses your own immune cells to attack lymphoma cells that have the CD30 protein. It is for people whose lymphoma has come back or not responded to at least 2 prior treatments.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.